Category: Uncategorized

THE ONLY REASON ELECTRONIC MEDICAL RECORDS DON'T EXIST IN THE US is because those with vested interest don't want transparency and accountability, and keep throwing up the specter of immense difficulty when challenged on it. I live in a small Spanish village. For decades they have had no paper in their medical clinic. They are 100% electronic. This US debate is sheer nonsense, and the sooner the public sees through the smokescreen, the better. Lack of transparency protects differential billing, duplication of services, and every inefficiency that gives the US off-the-charts medical costs. http://www.amazon.com/gp/aw/d/1567935605/ref=redir_mdp_mobile/191-2330943-1101115 View in LinkedIn

IN M&A NEGOTIATIONS, VALUATION IS USUALLY A HOT TOPIC. You may elect to avoid the topic entirely by structuring your deal as an EARN-OUT. This structure is silent on valuation, except implicitly in the percentage allocations, but a small percent of a large future sum is often more palatable than a tiny valuation at the start. View in LinkedIn

IN A FUTURE OF PRIVATIZED WATER SUPPLIES, this is a useful start for rural communities in developing countries. The privatization of water has already insidiously crept upon us with bottled water, unlabeled regarding its ingredients and impurities, and driven by a distrust of public water supplies. The concept of an aquifer output being privatized is at best troubling. This is one great challenge of this next 50 years. http://lnkd.in/6ivutr View in LinkedIn

GRAVEYARDS CAN SPOOK INVESTORS. Where an industry segment has had a history of several well-known failures, most investors will run a mile, regardless of whether the failures were different from your invention. Graveyards spoil fresh markets and are very difficult to enter. It is your job to know these histories, and it is prudent to avoid them. You do not need controversy to plague your funding. This is a shame because most graveyards have untapped markets and significant opportunities. View in LinkedIn

GENOMIC MEDICINE IS EMERGING AS A REALITY. Read this excellent interview with the head of the Scripps Institute. Idiopathic diseases will be a thing of the past. Mutational diagnostics will be be normative in medicine. This is the fruit of the Human Genome Project, and the inevitable emergence of a distinct and dramatic change in medicine: preventative medicine. http://lnkd.in/xyQQGZ View in LinkedIn

PUBLISHING ON DEMAND (POD) used to be called derisively the 'Vanity Press'. While the giant publishing houses either slept, entered a state of denial, or were paralyzed in the headlights, this ultimately logical solution to the lazy dominance of the publishing houses emerged. No editor gatekeepers, no giant warehousing issues, no tiny royalties for the authors. Just let the market decide. It is only a matter of time before this +- 30 Bn USD industry is turned in its head and David beats Goliath. Another industry democratized. http://www.theindependentpublishingmagazine.com/2013/03/is-hybrid-new-buzz-word-for-literary.html?m=1 View in LinkedIn

"BUT FOR LIFE'S INFIRMITIES,YOUTH WOULD NOT YIELD TO AGE" (King Lear). If it sounds too good to be true, it likely is. Reflect on the fact that deciduous trees loose their leaves in autumn. My explanation is that nature finds it more complex to mend a broken organ than to grow a new one. Skin is sloughed off daily. Hair is shed all the time. Repair is difficult and costly. http://lnkd.in/7u-EYF View in LinkedIn

3D PRINTING: A TECHNOLOGY WITH HIDDEN POSSIBILITIES? This technology may have deep and numerous uses, and truly unexpected applications that we have not yet conceived. All it needs is strong imaginations to drive applications. I wait to be surprised. http://lnkd.in/FGyuT5 View in LinkedIn

TRY AND AVOID BINARY OUTCOMES AS AN ENTREPRENEUR: SUCCESS OR FAILURE. For those developing a single product, like a single new drug, the outcome is binary. That can be heartbreaking for the entrepreneur after years of work, and rough on investors. Try always to have at least two candidates or products to hedge your bets, if possible without distracting yourself, and best still partner the second so your burn on it is minimized. A tall order, but better than the binary dilemma. View in LinkedIn

THE NOVARTIS CEO WANTS TO REINVENT THE BROKEN BIG PHARMA BUSINESS MODEL. Faced with the easy pickings having been made, patent expiries, new reimbursement gatekeepers, and patient-centric care, the old ways of doing business is now at an end for Big Pharma. Fortunately, there are many options. As Takeda is already proving, by outsourcing R&D to small, creative companies that are only good at invention, and have neither the desire, muscle, nor expertise to do the selling. Those unwilling or unable to change will likely be consumed as the world changes about them. http://lnkd.in/YCa7RF View in LinkedIn